PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
20.86%
Positive growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch would examine competitive advantages in a declining market.
17.29%
Cost increase while Drug Manufacturers - Specialty & Generic shows cost reduction. Peter Lynch would examine competitive disadvantages.
30.04%
Positive growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch would examine competitive advantages.
7.59%
Margin expansion while Drug Manufacturers - Specialty & Generic median declines. Peter Lynch would examine competitive advantages.
-60.00%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 78.18%. Seth Klarman would investigate competitive implications.
-7.96%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
67.21%
Marketing expense change of 67.21% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
132.35%
Other expenses growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
122.90%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 48.39%. Jim Chanos would check for waste.
105.50%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 20.90%. Jim Chanos would check for waste.
83.16%
Interest expense change of 83.16% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
-80.48%
D&A reduction while Drug Manufacturers - Specialty & Generic median is -8.61%. Seth Klarman would investigate efficiency.
-114.58%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is -172.39%. Seth Klarman would investigate causes.
-77.54%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is -198.76%. Seth Klarman would investigate causes.
-130.61%
Operating income decline while Drug Manufacturers - Specialty & Generic median is -179.71%. Seth Klarman would investigate causes.
-90.81%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is -208.75%. Seth Klarman would investigate causes.
130.66%
Other expenses growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
-75.82%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is -197.05%. Seth Klarman would investigate causes.
-45.47%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is -232.40%. Seth Klarman would investigate causes.
-10502.49%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is -171.48%. Seth Klarman would investigate advantages.
-61.23%
Net income decline while Drug Manufacturers - Specialty & Generic median is -206.97%. Seth Klarman would investigate causes.
-33.40%
Net margin decline while Drug Manufacturers - Specialty & Generic median is -245.94%. Seth Klarman would investigate causes.
100.00%
EPS growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
100.00%
Diluted EPS growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
-100.00%
Share count reduction while Drug Manufacturers - Specialty & Generic median is 3.06%. Seth Klarman would investigate strategy.
-100.00%
Diluted share reduction while Drug Manufacturers - Specialty & Generic median is 3.06%. Seth Klarman would investigate strategy.